腹部和盆腔全身及消融肿瘤治疗的非预期后果
本文探讨了当前使用的全身和消融抗癌疗法在腹部和盆腔影像检查中可能表现出的非预期后果,包括细胞毒性药物、分子靶向药物、免疫药物、消融治疗和造血干细胞移植。这些治疗可在靶器官、局部或邻近结构或远处部位产生主要和次要的非预期效应。影像医师及时识别并报告这些不良后果可促成关键的治疗调整和/或挽救生命的干预,因此放射科医师必须了解这些非预期效应。
要点
- 细胞毒性、分子靶向、免疫药物、消融及造血干细胞移植均可引起腹部盆腔影像上的非预期效应。
- 非预期效应可发生于靶器官、局部或邻近结构,也可发生于远处部位。
- 影像医师及时识别并报告抗癌治疗的不良后果,可促成关键治疗调整或挽救生命的干预。
核心结论
- 影像医师识别并报告抗癌治疗的非预期效应至关重要,可促成关键的治疗调整和/或挽救生命的干预。
研究设计与样本
- 本文为综述,探讨当前使用的全身和消融抗癌疗法在腹部和盆腔影像检查中可能表现出的非预期后果。
- 涵盖的治疗包括细胞毒性药物、分子靶向药物、免疫药物、消融治疗和造血干细胞移植。
临床应用与阅片要点
- 放射科医师解读癌症患者的影像检查结果时,必须了解这些非预期效应,以及时识别并报告抗癌治疗的不良后果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Human cancers are genetically complex and diverse. Although advances in oncologic therapy aim to define and target unique steps in carcinogenesis, oncologists often rely on less discriminate anticancer therapies that have consequences for normal tissues. Even many of the so-called targeted therapies currently employed can adversely affect normal cells, leading to complications that necessitate dose reductions or cessation of specific therapies. This article explores the unintended consequences of currently employed systemic and ablative anticancer therapies that might manifest at imaging examinations of the abdomen and pelvis, including cytotoxic, molecular targeted, and immunologic agents; ablation; and hematopoietic stem cell transplant. Each of these treatments can have both major and minor unintended effects in the targeted organ(s), in local or adjacent structures, or at distant sites. Timely detection and reporting of adverse consequences of anticancer therapies by the astute imager can result in critical treatment modifications and/or lifesaving interventions; therefore, knowledge of these unintended effects is paramount for radiologists interpreting the results of imaging examinations in cancer patients. ©RSNA, 2018.
引用
- Birch JC, Khatri G, Watumull LM, et al. Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis. Radiographics. 2018. PMID: 29995613. doi:10.1148/rg.2018170137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。